vs

Side-by-side financial comparison of ADTRAN Holdings, Inc. (ADTN) and CATALYST PHARMACEUTICALS, INC. (CPRX). Click either name above to swap in a different company.

ADTRAN Holdings, Inc. is the larger business by last-quarter revenue ($291.6M vs $152.6M, roughly 1.9× CATALYST PHARMACEUTICALS, INC.). CATALYST PHARMACEUTICALS, INC. runs the higher net margin — 34.5% vs -1.2%, a 35.8% gap on every dollar of revenue. On growth, ADTRAN Holdings, Inc. posted the faster year-over-year revenue change (20.1% vs 7.6%). CATALYST PHARMACEUTICALS, INC. produced more free cash flow last quarter ($44.9M vs $30.6M). Over the past eight quarters, CATALYST PHARMACEUTICALS, INC.'s revenue compounded faster (24.5% CAGR vs 13.5%).

Adtran, Inc. is an American fiber networking and telecommunications company headquartered in Huntsville, Alabama. It is a vendor of both residential and enterprise networking equipment, along with administrative software for network management and deployment. Its customers include communications service providers, governments, enterprises and utilities.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ADTN vs CPRX — Head-to-Head

Bigger by revenue
ADTN
ADTN
1.9× larger
ADTN
$291.6M
$152.6M
CPRX
Growing faster (revenue YoY)
ADTN
ADTN
+12.4% gap
ADTN
20.1%
7.6%
CPRX
Higher net margin
CPRX
CPRX
35.8% more per $
CPRX
34.5%
-1.2%
ADTN
More free cash flow
CPRX
CPRX
$14.3M more FCF
CPRX
$44.9M
$30.6M
ADTN
Faster 2-yr revenue CAGR
CPRX
CPRX
Annualised
CPRX
24.5%
13.5%
ADTN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ADTN
ADTN
CPRX
CPRX
Revenue
$291.6M
$152.6M
Net Profit
$-3.6M
$52.7M
Gross Margin
39.0%
82.9%
Operating Margin
1.5%
40.5%
Net Margin
-1.2%
34.5%
Revenue YoY
20.1%
7.6%
Net Profit YoY
92.2%
-5.8%
EPS (diluted)
$-0.02
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADTN
ADTN
CPRX
CPRX
Q4 25
$291.6M
$152.6M
Q3 25
$279.4M
$148.4M
Q2 25
$265.1M
$146.6M
Q1 25
$247.7M
$141.4M
Q4 24
$242.9M
$141.8M
Q3 24
$227.7M
$128.7M
Q2 24
$226.0M
$122.7M
Q1 24
$226.2M
$98.5M
Net Profit
ADTN
ADTN
CPRX
CPRX
Q4 25
$-3.6M
$52.7M
Q3 25
$-10.3M
$52.8M
Q2 25
$-20.5M
$52.1M
Q1 25
$-11.3M
$56.7M
Q4 24
$-46.1M
$55.9M
Q3 24
$-33.3M
$43.9M
Q2 24
$-49.7M
$40.8M
Q1 24
$-330.8M
$23.3M
Gross Margin
ADTN
ADTN
CPRX
CPRX
Q4 25
39.0%
82.9%
Q3 25
38.3%
84.7%
Q2 25
37.3%
85.9%
Q1 25
38.4%
87.3%
Q4 24
36.9%
84.7%
Q3 24
36.5%
85.0%
Q2 24
36.0%
87.4%
Q1 24
31.1%
87.3%
Operating Margin
ADTN
ADTN
CPRX
CPRX
Q4 25
1.5%
40.5%
Q3 25
-1.0%
44.7%
Q2 25
-5.0%
45.2%
Q1 25
-1.6%
44.8%
Q4 24
-6.9%
44.3%
Q3 24
-11.5%
39.6%
Q2 24
-17.0%
44.2%
Q1 24
-153.1%
27.5%
Net Margin
ADTN
ADTN
CPRX
CPRX
Q4 25
-1.2%
34.5%
Q3 25
-3.7%
35.6%
Q2 25
-7.7%
35.6%
Q1 25
-4.5%
40.1%
Q4 24
-19.0%
39.4%
Q3 24
-14.6%
34.1%
Q2 24
-22.0%
33.2%
Q1 24
-146.2%
23.6%
EPS (diluted)
ADTN
ADTN
CPRX
CPRX
Q4 25
$-0.02
$0.40
Q3 25
$-0.12
$0.42
Q2 25
$-0.24
$0.41
Q1 25
$-0.14
$0.45
Q4 24
$-0.58
$0.44
Q3 24
$-0.38
$0.35
Q2 24
$-0.63
$0.33
Q1 24
$-4.20
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADTN
ADTN
CPRX
CPRX
Cash + ST InvestmentsLiquidity on hand
$95.7M
$709.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$145.8M
$954.3M
Total Assets
$1.2B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADTN
ADTN
CPRX
CPRX
Q4 25
$95.7M
$709.2M
Q3 25
$93.7M
$689.9M
Q2 25
$106.3M
$652.8M
Q1 25
$101.3M
$580.7M
Q4 24
$76.0M
$517.6M
Q3 24
$88.5M
$442.3M
Q2 24
$111.2M
$375.7M
Q1 24
$106.8M
$310.4M
Stockholders' Equity
ADTN
ADTN
CPRX
CPRX
Q4 25
$145.8M
$954.3M
Q3 25
$141.6M
$920.2M
Q2 25
$169.6M
$856.0M
Q1 25
$138.9M
$794.3M
Q4 24
$127.0M
$727.6M
Q3 24
$205.6M
$660.9M
Q2 24
$213.6M
$608.7M
Q1 24
$260.8M
$561.4M
Total Assets
ADTN
ADTN
CPRX
CPRX
Q4 25
$1.2B
$1.1B
Q3 25
$1.2B
$1.1B
Q2 25
$1.2B
$971.9M
Q1 25
$1.2B
$908.9M
Q4 24
$1.2B
$851.4M
Q3 24
$1.3B
$772.0M
Q2 24
$1.3B
$706.4M
Q1 24
$1.3B
$646.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADTN
ADTN
CPRX
CPRX
Operating Cash FlowLast quarter
$42.2M
$44.9M
Free Cash FlowOCF − Capex
$30.6M
$44.9M
FCF MarginFCF / Revenue
10.5%
29.4%
Capex IntensityCapex / Revenue
4.0%
0.0%
Cash ConversionOCF / Net Profit
0.85×
TTM Free Cash FlowTrailing 4 quarters
$98.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADTN
ADTN
CPRX
CPRX
Q4 25
$42.2M
$44.9M
Q3 25
$12.2M
$32.4M
Q2 25
$32.2M
$71.3M
Q1 25
$43.2M
$60.0M
Q4 24
$2.4M
$70.9M
Q3 24
$43.3M
$72.9M
Q2 24
$19.9M
$64.1M
Q1 24
$37.9M
$31.9M
Free Cash Flow
ADTN
ADTN
CPRX
CPRX
Q4 25
$30.6M
$44.9M
Q3 25
$4.2M
Q2 25
$27.5M
$71.3M
Q1 25
$35.8M
Q4 24
$-895.0K
$70.8M
Q3 24
$37.1M
$72.6M
Q2 24
$8.4M
$64.1M
Q1 24
$24.4M
$31.7M
FCF Margin
ADTN
ADTN
CPRX
CPRX
Q4 25
10.5%
29.4%
Q3 25
1.5%
Q2 25
10.4%
48.6%
Q1 25
14.4%
Q4 24
-0.4%
49.9%
Q3 24
16.3%
56.4%
Q2 24
3.7%
52.3%
Q1 24
10.8%
32.2%
Capex Intensity
ADTN
ADTN
CPRX
CPRX
Q4 25
4.0%
0.0%
Q3 25
2.9%
0.0%
Q2 25
1.8%
0.0%
Q1 25
3.0%
0.0%
Q4 24
1.4%
0.1%
Q3 24
2.7%
0.2%
Q2 24
5.1%
0.0%
Q1 24
6.0%
0.2%
Cash Conversion
ADTN
ADTN
CPRX
CPRX
Q4 25
0.85×
Q3 25
0.61×
Q2 25
1.37×
Q1 25
1.06×
Q4 24
1.27×
Q3 24
1.66×
Q2 24
1.57×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADTN
ADTN

Subscriber Solutions$96.2M33%
Optical Networking Solutions$81.8M28%
Access Aggregation Solutions$64.6M22%
Services And Support$48.9M17%

CPRX
CPRX

Firdapse$97.6M64%
Agamree$35.3M23%
Fycompa$19.6M13%

Related Comparisons